Health Catalyst, Inc. HCAT R2K
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operations, measures and registries, and data and analytics. The company also provides expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. It serves academic medical centers, integrated delivery networks, community hospitals, large physician practices, accountable care organizations, health information exchanges, health insurers, life science organizations, healthcare technology vendors, and other risk-bearing entities. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -9.8% CAGR over 5 years.
- Trading 66.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HCAT Health Catalyst, Inc. R2K | 1.38 | - | $101.97M | - | -37.04% | -103.02% | 4.05% | -9.84% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.99M | 32.87M | 35.21M | 36.80M | 39.42M | 45.12M | 43.26M | 47.19M | 55.85M | 59.63M | 61.74M | 68.09M | 70.63M | 68.35M | 73.87M | 73.21M | 73.77M | 74.72M | 75.90M | 76.35M | 79.41M | 80.72M | 76.32M | 74.68M | 70.76M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.18M | 42.48M | 38.51M | 35.30M | 35.29M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.29M | 36.23M | 38.24M | 37.82M | 39.38M | 35.46M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.25M | 46.57M | 55.33M | 36.12M | 42.63M |
| Operating Income | -18.81M | -16.50M | -11.09M | -9.36M | -20.74M | -18.11M | -15.64M | -23.46M | -24.32M | -32.32M | -42.25M | -24.35M | -33.19M | -45.72M | -34.91M | -34.62M | -24.58M | -22.81M | -15.81M | -13.69M | -17.02M | -8.32M | -17.51M | 3.26M | -7.16M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.89M | -22.43M | -3.94M | -72.25M | -93.75M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.32M | 5.79M | 5.63M | 5.52M | 4.74M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.53M | -40.90M | -22.19M | -90.65M | -110.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 215.00K | 81.00K | 41.00K | 379.00K | 414.00K |
| Net Income | -19.32M | -16.88M | -13.72M | -10.69M | -21.42M | -17.49M | -27.18M | -27.33M | -28.37M | -35.83M | -40.01M | -22.46M | -33.43M | -45.73M | -33.19M | -32.61M | -22.03M | -20.59M | -13.52M | -14.73M | -23.74M | -40.98M | -22.23M | -91.03M | -111.03M |
| Diluted EPS | - | - | - | - | - | -0.47 | -0.71 | -0.68 | -0.65 | -0.80 | -0.82 | -0.54 | -0.62 | -0.84 | -0.60 | -0.58 | -0.39 | -0.35 | -0.23 | -0.24 | -0.35 | -0.59 | -0.32 | -1.28 | -1.53 |
| R&D Expense | 8.49M | 10.84M | 10.02M | 9.71M | 13.48M | 13.09M | 12.06M | 13.39M | 14.35M | 14.52M | 16.39M | 17.15M | 18.15M | 20.77M | 17.08M | 17.59M | 17.67M | 14.87M | 13.88M | 14.19M | 15.19M | 12.39M | 12.28M | - | 9.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 73.08M | 112.57M | 154.94M | 188.84M | - | 276.24M | 295.94M | 306.58M | 311.14M |
| Cost of Revenue | - | - | - | - | - | 143.05M | 164.10M | 165.81M | 159.46M |
| Gross Profit | - | - | - | - | - | 133.19M | 131.83M | 140.78M | 151.68M |
| Operating Expenses | - | - | - | - | - | 273.19M | 231.83M | 198.39M | 194.42M |
| Operating Income | -45.54M | -60.09M | -54.87M | -96.12M | - | -140.00M | -100.00M | -57.61M | -42.74M |
| EBITDA | - | - | - | - | - | -91.71M | -57.78M | -10.65M | -102.50M |
| Interest Expense | - | - | - | - | - | 7.24M | 7.29M | 17.09M | 24.25M |
| Pretax Income | - | - | - | - | - | -141.68M | -117.79M | -69.17M | -177.26M |
| Tax Provision | - | - | - | - | - | -4.28M | 356.00K | 333.00K | 716.00K |
| Net Income | -47.03M | -61.98M | -60.10M | -115.02M | - | -137.40M | -118.15M | -69.50M | -177.97M |
| Diluted EPS | - | - | -12.86 | -2.91 | - | -2.63 | -2.09 | -1.15 | -2.55 |
| R&D Expense | 28.47M | 38.59M | 46.25M | 53.52M | 62.73M | 75.68M | 72.63M | 57.95M | 49.77M |
Compounded Sales Growth
| 5 Years: | 4.05% |
| 1 Year: | -10.90% |
Compounded Profit Growth
| 5 Years: | -9.84% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -63.68% |
| 6 Months: | -50.18% |
| 3 Months: | -14.81% |
| 1 Month: | +8.66% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 110.97M | 302.36M | 577.74M | - | 752.29M | 701.81M | 858.93M | 502.64M |
| Current Assets | - | - | - | - | - | - | 427.80M | 393.40M | 465.65M | 169.31M |
| Cash & Equivalents | - | - | 28.43M | 18.03M | 91.95M | - | 116.31M | 106.28M | 249.65M | 50.81M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 47.97M | 60.29M | 57.18M | 59.13M |
| Total Liabilities | - | - | 75.90M | 101.72M | 301.64M | - | 327.28M | 334.89M | 493.72M | 256.86M |
| Current Liabilities | - | - | 41.81M | 48.22M | 88.04M | - | 82.51M | 89.03M | 325.85M | 89.57M |
| Long Term Debt | - | - | 18.81M | 48.20M | 168.99M | - | 226.52M | 228.03M | 151.18M | 151.62M |
| Total Debt | - | - | - | - | - | - | 247.97M | 249.07M | 402.26M | 171.24M |
| Total Equity | -206.41M | -259.48M | -374.77M | 200.64M | 276.10M | - | 425.01M | 366.92M | 365.21M | 245.78M |
| Shares Outstanding | - | - | - | - | - | - | 55.26M | 58.30M | 64.04M | 72.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.83M | -40.30M | -32.18M | -26.15M | - | -35.27M | -33.08M | 14.56M | 731.00K |
| Investing Cash Flow | 22.41M | 21.40M | -209.60M | -82.56M | - | -39.02M | 20.29M | -22.90M | 36.19M |
| Financing Cash Flow | 24.87M | 24.35M | 231.38M | 182.61M | - | -2.61M | 2.73M | 151.75M | -235.78M |
| Capital Expenditure | -2.47M | -2.08M | -2.02M | -7.78M | - | -17.41M | -14.31M | -16.40M | -21.55M |
| Free Cash Flow | -39.30M | -42.37M | -34.20M | -33.92M | - | -52.68M | -47.39M | -1.84M | -20.82M |
| Net Change in Cash | - | - | - | - | - | -76.90M | -10.06M | 143.40M | -198.86M |
| Share Buybacks | 0 | 8.71M | 0 | 0 | 0 | 8.39M | 1.81M | 0 | 5.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 48.2% | 44.5% | 45.9% | 48.7% |
| Operating Margin % | -62.3% | -53.4% | -35.4% | -50.9% | - | -50.7% | -33.8% | -18.8% | -13.7% |
| Net Margin % | -64.4% | -55.1% | -38.8% | -60.9% | - | -49.7% | -39.9% | -22.7% | -57.2% |
| ROE % | 18.1% | 16.5% | -30.0% | -41.7% | - | -32.3% | -32.2% | -19.0% | -72.4% |
| ROCE % | - | -86.9% | -21.6% | -19.6% | - | -20.9% | -16.3% | -10.8% | -10.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 17.43% | 12.88M | $17.77M |
| 2 | Cdc Financial, Inc. | 8.54% | 6.31M | $8.70M |
| 3 | Blackrock Inc. | 6.95% | 5.14M | $7.09M |
| 4 | Whetstone Capital Advisors, LLC | 5.78% | 4.27M | $5.89M |
| 5 | Palogic Value Management, LP | 3.92% | 2.90M | $4.00M |
| 6 | Vanguard Capital Management LLC | 3.91% | 2.89M | $3.98M |
| 7 | Impax Asset Management Group plc | 3.72% | 2.75M | $3.79M |
| 8 | Nepsis, Inc. | 2.54% | 1.88M | $2.59M |
| 9 | Geode Capital Management, LLC | 2.03% | 1.50M | $2.07M |
| 10 | State Street Corporation | 1.79% | 1.32M | $1.83M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HCAT